EPS8L2 Antibody

What is EPS8L2 and what is its biological significance in research contexts?

EPS8L2 (epidermal growth factor receptor pathway substrate 8-like protein 2) is a member of the Eps8-like protein family and has been identified as a hair bundle protein that localizes at the tips of stereocilia . It has a calculated molecular weight of 81 kDa (715 amino acids) but is typically observed at 81-85 kDa in experimental settings . The protein is encoded by the EPS8L2 gene (Gene ID: 64787) and has been assigned UniProt ID Q9H6S3 .

From a research perspective, EPS8L2 is particularly interesting as it shares structural similarities with EPS8, which has established roles in actin cytoskeleton regulation and growth factor-mediated signal transduction. Notably, EPS8L2 has been identified as a putative substrate for NleH1 kinase activity , suggesting its involvement in phosphorylation-dependent signaling pathways that may be manipulated during bacterial infections. This connection makes EPS8L2 a valuable target for studies exploring host-pathogen interactions and cytoskeletal regulation mechanisms.

What experimental applications are validated for EPS8L2 antibodies?

EPS8L2 antibodies have been validated for multiple research applications, enabling comprehensive investigation of this protein in various experimental contexts:

Published literature includes experimental validation of EPS8L2 antibodies in western blot, immunohistochemistry, and immunofluorescence applications , providing researchers with confidence in these methodologies for studying this protein.

How can I confirm antibody specificity for EPS8L2 in my experimental system?

Confirming antibody specificity is critical for generating reliable data with EPS8L2 antibodies. A systematic approach should include:

• Positive control selection: Use validated cell lines known to express EPS8L2, such as HeLa, A431, or HepG2 cells for human studies, or mouse skin tissue for murine research .

• Multiple validation techniques:

  • Western blot: Look for a distinct band at 81-85 kDa in positive control lysates .

  • Peptide competition assay: Pre-incubation with the immunizing peptide should abolish specific staining.

  • Genetic knockdown/knockout: RNAi or CRISPR-based reduction of EPS8L2 should result in corresponding signal reduction.

• Cross-reactivity assessment: If working with species other than human or mouse (the validated reactivity species ), perform sequence alignment analysis to evaluate potential epitope conservation.

• Application-specific considerations:

  • For IHC: Include isotype controls and no-primary-antibody controls.

  • For IF: Compare staining patterns with published subcellular localization data.

  • For IP: Confirm pulled-down protein identity by Western blot or mass spectrometry.

Thorough validation not only ensures experimental reliability but also helps optimize antibody working conditions for your specific research system.

What are optimal sample preparation protocols for detecting EPS8L2?

Effective sample preparation is crucial for successful EPS8L2 detection across different applications. Based on experimental evidence, the following protocols are recommended:

For Western Blot analysis:

• Cell lysis using RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) with freshly added protease inhibitors.

• Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) if investigating phosphorylation states, particularly relevant since EPS8L2 is a putative kinase substrate .

• Protein determination using Bradford or BCA assay.

• Load 20-50 μg of total protein per lane.

• Use 8-10% polyacrylamide gels to achieve optimal resolution in the 80-90 kDa range.

• Transfer to PVDF membranes (preferred over nitrocellulose for proteins >70 kDa).

• Block with 5% non-fat milk or BSA in TBST.

For Immunohistochemistry:

• Tissue fixation with 10% neutral buffered formalin.

• Paraffin embedding and sectioning at 4-6 μm thickness.

• Antigen retrieval preferably using TE buffer pH 9.0, or alternatively, citrate buffer pH 6.0 .

• Block endogenous peroxidase activity with 3% H₂O₂.

• Block non-specific binding with 5-10% normal serum.

• Primary antibody incubation (1:50-1:500) overnight at 4°C.

For Immunofluorescence:

• Cell fixation with 4% paraformaldehyde (10-15 minutes at room temperature).

• Permeabilization with 0.1-0.3% Triton X-100 in PBS (5-10 minutes).

• Blocking with 5% normal serum in PBS containing 0.1% Triton X-100.

• Primary antibody incubation (1:10-1:100) overnight at 4°C.

• Counter-staining with DAPI and phalloidin recommended for localization studies.

Optimization of these protocols for your specific experimental system is advisable, as sensitivity and specificity can vary between different cell types and tissues.

How can I optimize EPS8L2 antibody performance for challenging applications?

When facing challenges with EPS8L2 detection, particularly in low-expressing samples or for difficult applications, several optimization strategies can improve results:

For enhancing Western blot sensitivity:

• Signal amplification: Consider using HRP-conjugated polymer detection systems rather than standard secondary antibodies.

• Membrane selection: PVDF membranes typically offer better protein retention and sensitivity than nitrocellulose for EPS8L2 detection.

• Extended antibody incubation: Overnight primary antibody incubation at 4°C may improve signal compared to shorter incubations.

• Sample enrichment: Consider immunoprecipitation to concentrate EPS8L2 before Western blot analysis.

• Reducing agents: Fresh DTT or β-mercaptoethanol in sample buffer ensures proper protein denaturation.

For improving IHC/IF specificity:

• Titration experiments: Test a dilution series from 1:10 to 1:500 to identify optimal antibody concentration .

• Antigen retrieval optimization: Compare heat-mediated retrieval with TE buffer pH 9.0 versus citrate buffer pH 6.0 .

• Background reduction: Add 0.1-0.3% Triton X-100 and 1-5% BSA to antibody diluent.

• Buffer modifications: Increasing salt concentration (up to 300-500 mM NaCl) in wash buffers can reduce non-specific binding.

• Sequential double staining: When co-staining, complete one staining sequence before starting the second to avoid cross-reactivity.

For successful immunoprecipitation:

• Antibody amount optimization: Test a range from 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate .

• Pre-clearing lysates: Incubate with protein A/G beads before adding antibody to reduce non-specific binding.

• Extended binding time: Allow antibody-lysate binding overnight at 4°C with gentle rotation.

• Washing stringency: Use graduated washing stringency (low to high salt) to preserve specific interactions.

These optimization strategies should be systematically tested to determine the most effective approach for your specific research question and experimental system.

How should I design controls for experiments using EPS8L2 antibodies?

Proper experimental controls are essential for generating reliable and interpretable data when working with EPS8L2 antibodies. A comprehensive control strategy should include:

Positive controls:

• Validated expressing cells/tissues: HeLa cells, A431 cells, HepG2 cells for human studies; mouse skin tissue for murine studies .

• Recombinant protein: Purified or overexpressed EPS8L2 protein as a reference standard.

• Known biological context: Samples where EPS8L2 function or regulation has been previously characterized.

Negative controls:

• Technical controls:

  • Omit primary antibody while maintaining all other steps to assess secondary antibody specificity.

  • Use isotype-matched non-specific IgG to evaluate background binding.

  • Include blocking peptide competition to confirm epitope specificity.

• Biological controls:

  • Cells with EPS8L2 knockdown or knockout (siRNA, shRNA, or CRISPR-Cas9 modified).

  • Tissues or cell types with naturally low or absent EPS8L2 expression.

  • Comparing related family members (e.g., EPS8, EPS8L1, EPS8L3) to assess cross-reactivity.

Procedural controls:

• Loading controls: β-actin, GAPDH, or total protein staining for Western blots.

• Cross-application validation: Confirm results using complementary methods (e.g., IF findings with Western blot).

• Antibody titration: Include a range of antibody dilutions to identify optimal signal-to-noise ratio.

Implementing this comprehensive control strategy ensures experimental rigor and facilitates troubleshooting if unexpected results are observed.

How can I investigate EPS8L2 phosphorylation in the context of kinase interactions?

Investigating EPS8L2 phosphorylation, particularly in relation to kinases like NleH1 that have been identified as potential regulators , requires specialized approaches:

In vitro phosphorylation assays:

• Recombinant protein preparation: Express and purify EPS8L2 full-length protein or relevant domains.

• Kinase reaction: Incubate purified EPS8L2 with recombinant kinases (e.g., NleH1) in the presence of ATP.

• Detection methods:

  • Radioactive assay using [γ-³²P]ATP

  • Thiophosphate labeling with ATP-γS followed by alkylation and detection with anti-thiophosphate antibodies

  • Mass spectrometry to identify specific phosphorylation sites

Site-directed mutagenesis approach:

• Candidate site identification: Align EPS8L2 sequence with Eps8 to identify conserved serine residues that might correspond to Ser775 in Eps8, which is phosphorylated by NleH kinases .

• Mutant construction: Generate serine-to-alanine substitutions at candidate phosphorylation sites.

• Comparative analysis: Test phosphorylation of wild-type versus mutant proteins to identify specific phosphorylation sites.

Cellular assays:

• Co-expression studies: Express EPS8L2 with wild-type or kinase-dead mutants of NleH1 in cell culture.

• Infection models: Compare EPS8L2 phosphorylation in cells infected with wild-type versus ΔnleH1ΔnleH2 mutant bacteria .

• Phospho-specific antibody development: Generate antibodies recognizing specific phosphorylated residues in EPS8L2.

• Phospho-enrichment: Use phospho-peptide enrichment techniques combined with mass spectrometry to identify in vivo phosphorylation sites.

Functional consequences assessment:

• Localization studies: Examine whether phosphorylation affects subcellular localization of EPS8L2.

• Protein interaction studies: Determine if phosphorylation alters EPS8L2 binding to partners.

• Activity assays: Assess whether phosphorylation affects putative actin-related functions, similar to how phosphorylation affects Eps8 bundling activity .

This multi-faceted approach can provide detailed insights into the regulatory mechanisms controlling EPS8L2 function through phosphorylation.

What is the role of EPS8L2 in cytoskeletal organization and can it be studied experimentally?

Based on its homology to Eps8 and the available research data, EPS8L2 likely plays a role in cytoskeletal organization, particularly in specialized cellular structures. This function can be investigated through several experimental approaches:

Structural localization studies:

• High-resolution microscopy: Utilize super-resolution techniques (STED, STORM, SIM) to precisely localize EPS8L2 in relation to cytoskeletal elements.

• Co-localization analysis: Examine association with actin filaments and actin-regulatory proteins using quantitative co-localization methods.

• Specialized cell models: Study EPS8L2 in polarized epithelial cells, stereocilia-bearing cells, or other models with specialized actin-rich structures.

• Live cell imaging: Monitor dynamics of fluorescently tagged EPS8L2 in relation to cytoskeletal remodeling in real-time.

Functional assays:

• Actin bundling assays: Similar to those conducted for Eps8 , assess whether EPS8L2 has actin bundling capacity using purified proteins.

• Knockdown/knockout phenotype analysis: Evaluate cytoskeletal architecture changes following EPS8L2 depletion.

• Rescue experiments: Test whether EPS8L2 can functionally substitute for Eps8 in Eps8-deficient systems.

• Domain function analysis: Create truncation or point mutation constructs to identify domains critical for cytoskeletal interactions.

Disease-relevant models:

• Infection models: Examine EPS8L2 contribution to cytoskeletal remodeling during bacterial infections, particularly those involving attaching and effacing (AE) lesion formation by EPEC .

• Polarized cell systems: Investigate EPS8L2 role in microvilli or stereocilia formation using LS174T-W4 cells treated with doxycycline to induce polarization .

• Tissue-specific studies: Analyze EPS8L2 function in tissues where specialized actin structures are important (e.g., inner ear hair cells, intestinal brush border).

Protein interaction mapping:

• Yeast two-hybrid screening: Identify novel EPS8L2-interacting proteins involved in cytoskeletal regulation.

• Proximity labeling: Use BioID or APEX2 fusions to identify proteins in close proximity to EPS8L2 in living cells.

• Co-immunoprecipitation: Analyze EPS8L2 interactome under different cellular conditions.

• Domain-specific interactions: Determine if the SH3 domain of EPS8L2 interacts with proline-rich motifs in cytoskeletal regulators, similar to the interactions observed between Eps8 and NleH kinases .

These approaches provide a comprehensive framework for investigating the role of EPS8L2 in cytoskeletal organization across different biological contexts.

What methodologies can reveal EPS8L2 involvement in specialized cellular structures?

EPS8L2's potential involvement in specialized cellular structures, particularly actin-rich formations like stereocilia and microvilli, can be investigated using advanced methodological approaches:

Advanced microscopy techniques:

• Electron microscopy:

  • Immunogold labeling for precise localization at ultrastructural level

  • Correlative light and electron microscopy (CLEM) to combine fluorescence and ultrastructural data

  • Transmission EM of specialized structures in tissues following EPS8L2 manipulation

• Super-resolution fluorescence microscopy:

  • Structured illumination microscopy (SIM) for 2x improvement in resolution

  • Stimulated emission depletion (STED) microscopy for visualization of fine structures

  • Single-molecule localization microscopy (PALM/STORM) for nanoscale protein distribution

• Live-cell imaging:

  • Fluorescence recovery after photobleaching (FRAP) to assess EPS8L2 dynamics

  • Single-particle tracking of tagged EPS8L2 to monitor mobility and interactions

  • Förster resonance energy transfer (FRET) to study protein-protein interactions in situ

Biochemical fractionation approaches:

• Differential centrifugation to separate cellular compartments and analyze EPS8L2 distribution

• Detergent-resistant membrane isolation to examine association with specialized membrane domains

• Actin co-sedimentation assays to assess direct binding to filamentous actin

• Cross-linking mass spectrometry to capture transient interactions in specialized structures

Genetic manipulation strategies:

• Tissue-specific conditional knockout models focusing on tissues with prominent specialized structures

• CRISPR-Cas9 genome editing to tag endogenous EPS8L2 or introduce domain-specific mutations

• Inducible expression systems to study temporal aspects of EPS8L2 function during structure formation

• Rescue experiments with structure-specific targeting of EPS8L2 to determine sufficiency for localization

Specialized cellular models:

• Organoid systems that develop polarized epithelial structures with microvilli

• Inner ear hair cell models for studying stereocilia formation and maintenance

• Primary intestinal epithelial cultures to examine brush border formation

• Bacterial infection models to study EPS8L2 dynamics during pathogen-induced cytoskeletal remodeling, similar to studies performed with Eps8

By combining these methodologies, researchers can comprehensively characterize the role of EPS8L2 in specialized cellular structures across diverse biological contexts.

How should I address inconsistent EPS8L2 antibody staining patterns?

Inconsistent staining patterns are a common challenge when working with EPS8L2 antibodies. A systematic troubleshooting approach can help identify and resolve these issues:

For Western blot inconsistencies:

• Sample preparation issues:

  • Ensure complete protein denaturation (heat samples at 95°C for 5 minutes in fresh sample buffer)

  • Confirm equal protein loading using total protein stains or housekeeping proteins

  • Add protease and phosphatase inhibitors immediately upon lysis

  • Consider fresh samples, as freeze-thaw cycles may affect EPS8L2 integrity

• Technical parameters:

  • Optimize transfer efficiency for higher molecular weight proteins (81-85 kDa)

  • Test different membrane types (PVDF often performs better than nitrocellulose for EPS8L2)

  • Adjust blocking conditions (compare 5% milk versus 5% BSA)

  • Try a range of primary antibody dilutions within recommended range (1:1000-1:6000)

For immunostaining inconsistencies:

• Fixation and antigen retrieval optimization:

  • Compare different fixatives (paraformaldehyde, methanol, acetone)

  • Test multiple antigen retrieval methods, with emphasis on TE buffer pH 9.0 versus citrate buffer pH 6.0

  • Optimize retrieval time and temperature

• Antibody penetration issues:

  • Increase permeabilization time/detergent concentration

  • Try antibody incubation at room temperature versus 4°C

  • For thick tissue sections, consider longer incubation times

• Signal-to-noise ratio improvement:

  • Increase washing steps (number and duration)

  • Test different blocking agents (normal serum, BSA, commercial blockers)

  • Include detergents (0.1-0.3% Triton X-100) in antibody dilution buffers

For biological variability assessment:

• Expression level variation:

  • Verify EPS8L2 expression levels in your specific samples by qRT-PCR

  • Consider tissue/cell type-specific expression patterns

  • Assess if experimental treatments might alter EPS8L2 expression or localization

• Post-translational modifications:

  • Investigate if treatments induce phosphorylation (known to occur with related Eps8 protein)

  • Test if phosphorylation affects antibody recognition using phosphatase treatment

Systematic documentation of all variables and changes during troubleshooting will help identify the specific factors affecting your experimental results and lead to consistent, reproducible staining patterns.

What factors should I consider when analyzing EPS8L2 expression in different experimental contexts?

When analyzing EPS8L2 expression across different experimental contexts, multiple factors should be considered to ensure accurate data interpretation:

Biological variables affecting expression:

• Cell type-specific expression patterns: EPS8L2 expression varies across cell types, with validated detection in epithelial cell lines such as HeLa, A431, and HepG2 .

• Tissue context: Expression patterns may differ between tissue types, with documented expression in tissues like mouse skin and potential enrichment in tissues with specialized actin structures.

• Developmental stage: Consider whether EPS8L2 expression changes during development, particularly in tissues where specialized structures like stereocilia develop.

• Disease state: Evaluate whether pathological conditions alter EPS8L2 expression, particularly in contexts involving cytoskeletal reorganization.

• Experimental manipulations: Treatments that affect actin cytoskeleton organization or EGFR pathway activation may modulate EPS8L2 expression or localization.

Technical considerations for expression analysis:

• Method complementarity: Combine multiple detection methods (Western blot, qRT-PCR, immunostaining) to cross-validate expression findings.

• Antibody validation: Confirm specificity in your experimental system using appropriate controls (knockdown, competitive inhibition, multiple antibodies).

• Subcellular localization: EPS8L2 may concentrate in specific cellular compartments, potentially affecting extraction efficiency or detection sensitivity.

• Quantification approaches: For Western blot, normalize to appropriate loading controls; for immunostaining, use standardized image acquisition and analysis protocols.

• Expression versus activation: Consider that protein levels may remain constant while functional state changes through post-translational modifications like phosphorylation .

Contextual data interpretation:

• Relationship to EPS8 family members: Analyze whether EPS8L2 expression correlates with or compensates for other family members (EPS8, EPS8L1, EPS8L3).

• Interaction partners: Assess whether expression of known or predicted interaction partners correlates with EPS8L2 expression patterns.

• Functional correlates: Connect expression data with functional outcomes related to cytoskeletal organization or specialized cellular structures.

• Significance thresholds: Establish appropriate statistical approaches for determining significant differences in expression between experimental conditions.

By systematically addressing these factors, researchers can develop a more comprehensive understanding of EPS8L2 expression and function across diverse experimental contexts.

How can I distinguish between specific and non-specific signals when using EPS8L2 antibodies?

Distinguishing specific from non-specific signals is critical for generating reliable data with EPS8L2 antibodies. Multiple validation strategies can help confirm signal specificity:

Molecular weight verification (Western blot):

• Expected size confirmation: EPS8L2 should appear at 81-85 kDa . Bands at significantly different molecular weights may represent non-specific binding or degradation products.

• Multiple antibodies comparison: If possible, use antibodies targeting different EPS8L2 epitopes - specific signals should appear at the same molecular weight.

• Loading gradient analysis: Specific signals should change proportionally with increasing protein amounts, while non-specific bands may not follow this pattern.

• Peptide competition: Pre-incubating the antibody with immunizing peptide should selectively eliminate specific bands while non-specific signals typically remain.

Genetic validation approaches:

• Expression modulation: siRNA/shRNA knockdown or CRISPR knockout of EPS8L2 should reduce specific signals proportionally to knockdown efficiency.

• Overexpression controls: Overexpressed EPS8L2 (wild-type or tagged) should show increased signal intensity at the expected molecular weight.

• Rescue experiments: Re-expression of EPS8L2 in knockout cells should restore specific signals.

Immunostaining specificity verification:

• Subcellular localization consistency: Specific staining should show consistent patterns across similar cell types and match known biology (e.g., localization to stereocilia tips) .

• Colocalization with markers: EPS8L2 should colocalize with appropriate markers of structures where it's expected (e.g., F-actin in specialized structures).

• Signal ablation controls: Include controls where primary antibody is omitted or replaced with isotype-matched non-specific IgG.

• Signal competition: Pre-incubation with immunizing peptides should abolish specific staining.

Advanced specificity validation:

• Immunoprecipitation-Western blot: IP followed by Western blot analysis should confirm the same molecular weight species.

• Mass spectrometry validation: For definitive confirmation, immunoprecipitated proteins can be identified by mass spectrometry.

• Cross-reactivity assessment: Test antibody against related proteins (EPS8, EPS8L1, EPS8L3) to confirm specificity within the protein family.

By employing multiple orthogonal validation strategies, researchers can confidently distinguish between specific EPS8L2 signals and non-specific background, leading to more reliable and reproducible research outcomes.

Future directions for EPS8L2 antibody-based research

EPS8L2 antibody applications continue to evolve as researchers explore this protein's functions in various biological contexts. Future research directions should focus on several promising areas:

The emerging role of EPS8L2 in specialized cellular structures, particularly in relation to its phosphorylation by kinases like NleH1 , presents opportunities for deeper investigation of cytoskeletal regulation mechanisms. Development of phospho-specific antibodies targeting key regulatory sites would significantly advance our understanding of EPS8L2 functional states in both normal physiology and disease conditions.

Integration of EPS8L2 antibodies with emerging technologies, including super-resolution microscopy and proximity labeling approaches, will provide unprecedented insights into this protein's spatial organization and interaction networks. Additionally, exploring EPS8L2's potential involvement in pathological processes, such as during bacterial infections where NleH kinases are active , may reveal new therapeutic targets.

By continuing to refine antibody-based detection methods and combining them with complementary molecular and genetic approaches, researchers will develop a more comprehensive understanding of EPS8L2's biological roles and significance in health and disease.